ArticleMaterials today. Bio2025
Synergetic regulation of osteoimmune microenvironment and osteogenesis by decellularized amnion membrane for guided bone regeneration.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoregulatory properties of guided bone regeneration (GBR) membranes are essential for modulating the osteoimmune microenvironment to enhance osteogenesis. Decellularized amnion membrane (DAM), an extracellular matrix material derived from the placenta through the removal of cells and antigenic components, has attracted attention due to its low immunogenicity and rich composition. This study investigated the role of DAM in modulating the immune microenvironment, its impact on osteogenesis, and associated mechanisms during the GBR process. DAM exhibited high biocompatibility and directly promoted osteogenesis in vitro. Furthermore, DAM induced macrophage M2 polarization, mitigated oxidative stress under inflammatory contexts, and optimized the immune microenvironment, thereby indirectly enhancing cell migration and osteogenic differentiation. Multi-omics analysis revealed a crucial role of the PI3K-Akt signaling pathway, coordinated with immune-related TLR and TNF signaling pathways, in this process-highlighting the potential applications of DAM in the treatment of inflammatory bone defects. DAM's abundant bioactive components and distinctive three-dimensional architecture enable this synergistic effect. In vivo, DAM effectively inhibited inflammation and accelerated bone regeneration in a rat model of critical-size cranial defects. This study demonstrates that DAM possesses strong osteoimmunomodulatory properties and elucidates its underlying mechanisms in bone regeneration, making it a promising GBR membrane for clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.